Eli Lilly has entered two key collaboration deals on the same day in a bid to expand its metabolic portfolio. The company has agreed to collaborate with drug discovery biotech, Evotec, in a deal worth up to US$1 B, to develop treatments for metabolic diseases such as diabetes and kidney disease. Lilly also announced it is committing a further US$258 M to partner with Abbikso Therapeutics to develop novel molecules against an undisclosed target for cardiometabolic diseases. This metabolic focus comes as Lilly awaits the US FDA’s decision on its type 2 diabetes drug, tirzepatide.